Cardiac Event Monitor Market will reach $4.8 billion by 2023 Cardiac Event Monitor Market 2023 | Página 2

According to Susan Eustis, principal author of the study, “In an increasingly connected world, the
convergence of vital signs technologies with cardiac event monitoring technologies is able to
facilitate healthy living. This fits very well with cardiac equipment vendor core strengths in
professional healthcare and in consumer health and well-being.”
Disruptive technologies, disruptive services offerings change cardiac event recorder markets,
clinicians are leveraging technology to save lives.
A cardiac event recorder is a battery-powered portable miniature device. Devices record heart's
electrical activity (ECG) to detect presence of symptoms. Event recorders can be a loop memory
monitor and a symptom event monitor with newer devices containing internal analytics and the
ability to notify a physician directly if an event is detected. Cardiac event ambulatory monitors can
detect arrhythmias and get people to treatment faster before it is too late. Units are useful in the
fight to correct congestive heart failure even after it has been initiated.
Shortness of breath is a common symptom of cardiac disease. It is frequently misdiagnosed as a
respiratory symptom or ignored by patients and is not even considered a symptom. Detection of
heart disease is supported with the newer cardiac event recorders. Early treatment is essential
and the technology is a vital aid in providing that treatment.
Related reports by Radiant Insights: http://www.radiantinsights.com/catalog/medical-
devices
Other, newer technologies are emerging. A vital signs patch supports continuous, non-invasive
monitoring of EKG, Heart Rate, respiration rate, surface temperature, and arterial blood oxygen
saturation. The device is an easy-to-use sensor worn on a patient’s upper chest. It is intended to
be used on adult patients in a clinical environment.
The intended use group is adults 21 and above. Units are prescribed by a physician or other
qualified healthcare professional. Upon activation and connectivity to the supporting system, the
VSP provides automation and alerts of key vital signs via continuous wireless monitoring.
Considerable interest and effort has been put into patch-based devices aimed at improving
convenience for the patient and achieving better compliance. MCT 1-lead patches have been
developed. Medtronic’s SEEQ device is such a unit.
BioTelemetry’s CardioNet MCOT and Preventice BodyGuardian Heart have devices. The newer
patch based devices rely on MCT technology, iRhythm, a US-based AECG specialist, is selling a
somewhat differentiated patch, Zio XT. Similar to Holter monitoring, the device can record
arrhythmias.
It can record 10 days of continuous data, which is retrieved after completion of the monitoring, ie
not live transmission like in MCT. Cardiologists would hardly be able to handle such large amounts
of data, therefore iRhythm has developed proprietary algorithms, which provide summary reports.
Follow Us: